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Delayed graft function influences renal function,
but not survival
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the transplantation of kidneys from female donors to maleDelayed graft function influences renal function, but not survival.
recipients, and a prolonged cold ischemia time are potentiallyBackground. In renal transplantation, the impact of delayed
avoidable. Although DGF is one of the several risk factors ofgraft function (DGF) on prognosis is controversial. We ana-
acute rejection and suboptimal function at one year, it is notlyzed the risk factors of DGF and its impact on graft function
independently associated with an increased rate of graft loss.and prognosis.
Methods. Seven hundred thirty-four cadaveric renal trans-
plants performed between 1983 and 1997 were analyzed. DGF
was diagnosed when serum creatinine levels increased, remained In renal transplantation, there is controversy regardingunchanged, or decreased less than 10% per day in three consec-
the impact of delayed graft function (DGF) on long-utive days in the first week after transplantation. Creatinine
term outcome. This may relate to different criteria usedclearances of more or less than 50 or 30 mL/min at one year
were used as cut-off points for optimal and suboptimal graft to define DGF or to differences in data analysis. Most
function, respectively. The logistic regression model was used authors use the need for dialysis within the first week
to identify independent risk factor related to DGF and renal as the diagnostic inclusion criterion, but this does notfunction one year after transplantation. The Cox regression
differentiate the various causes of DGF such as ischemia-model was used to examine the influence of DGF on long-
reperfusion injury or early acute rejection episodes. Interm graft survival.
Results. Multivariate analysis revealed the following risk fac- addition, the degree of renal damage is often not taken
tors for DGF: recipient pretransplantation mean arterial blood into consideration. In the UNOS registry, DGF, defined
pressure of less than 100 mm Hg (OR 5 2.08, 95% CI, 1.43 to as the need for dialysis in the first week after transplanta-3.03), female donor to male recipient combination (OR 5 1.55,
tion, had a significant and independent impact on graft95% CI, 1.02 to 2.35), donor age of more than 50 years (OR 5
half-life. This effect was distinct from cold ischemia time2.21, 95% CI, 1.49 to 3.26), cold ischemia time of more than
28 hours (OR 5 1.78, 95% CI, 1.19 to 2.63), and peak panel (CIT), occurrence of acute rejection episodes, donor age,
reactive antibodies of more than 50% (OR 5 1.7, 95% CI, and serum creatinine levels [1, 2]. Others found a detri-
1.15 to 2.55). The incidence of DGF was one of the independent mental effect of DGF, also defined as the need for dial-
risk factors for suboptimal graft function at one year (OR 5
ysis in the first week, on graft survival only when it was1.68, 95% CI, 1.14 to 2.48), together with donor age of more
complicated by one or more acute rejection episodesthan 50 years (OR 5 2.39, 95% CI, 1.61 to 3.57), female donor
[3, 4]. Using the time required to reach a Cockroft renalgender (OR 5 1.99, 95% CI, 1.42 to 2.78), the occurrence of
acute rejection episodes (OR 5 2.66, 95% CI, 1.87 to 3.78), clearance of more than 10 mL/min, DGF lasting for more
peak panel-reactive antibodies of more than 50% (OR 5 1.67, than six days had a deleterious effect on graft survival,
95% CI, 1.15 to 2.47), and sharing of 1 to 3 versus 4 to 8 cross- whereas DGF of shorter duration did not influence graftreactive antigens groups (OR 5 1.65, 95% CI, 1.09 to 2.49).
survival [5]. In the present study, we analyzed the riskMoreover, DGF was one of the two independent risk factors
factors of DGF defined by stringent criteria, independentfor acute rejection episodes, but it had no independent effect
on graft survival. from the need of dialysis. Moreover, as graft function at
Conclusion. Several risk factors for DGF were identified, of one year is a strong surrogate marker of late graft out-
which a low recipient pretransplant mean arterial blood pressure, come [6, 7], we also studied the impact of DGF on one-
year graft function, graft loss, and long-term prognosis.
Key words: transplantation, cadaveric renal transplantation, ischemia-
reperfusion injury, acute graft rejection, kidney graft function.
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were included in the study. Kidneys were allocated ac- Creatinine clearance 5 [(140 2 age) 3 weight (kg)
cording to the matching and allocation criteria of Euro-
3 (A)/(serum creatinine (mmol/L) 3 0.8)]
transplant. We aimed to accept kidneys with no more
than two human lymphocyte antigen (HLA) mismatches in which A 5 1 in males and A 5 0.85 in females.
with a priority for HLA-DR matching.
Study design
Immunosuppressive regimen Risk factors of DGF and the impact of DGF on renal
The standard immunosuppressive regimen consisted function within the first year were analyzed and com-
of prednisone and cyclosporine A [Sandimmune (CsA)]. pared with grafts experiencing PF. Moreover, a broad
Sixty-two patients (8.4%) did not receive CsA and were spectrum of donor-, recipient-and transplantation-related
initially treated with azathioprine (Aza) in a dosage of variables was studied (Table 1). Acute rejection episodes
2 mg/kg/day. Two hundred seven (28%) patients initially were diagnosed on clinical grounds and confirmed by
treated with CsA were randomly or on clinical grounds biopsy, unless a biopsy could not be obtained. Rejections
converted to Aza within the first six post-transplant were classified as predominantly interstitial or vascular,
months. CsA was administered intravenously in a dose although most vascular rejections had variable degrees
of 3 mg/kg/day for the first 48 hours, starting at the onset of interstitial inflammation. Mean arterial blood pressure
of surgery. The initial oral dose of CsA was 10 mg/kg/ (MAP) was calculated using the following formula:
day from day 2 onward, divided in three daily doses, and
MAP 5 (diastolic blood pressure 3 2subsequently tapered. Doses were adjusted according to
CsA trough levels. After six weeks, the total dose was 1 systolic blood pressure)/3
given as a once daily dose. In the first three months, the
Cross-reactive groups (CREGs) were defined as thetarget 24-hour CsA trough level was between 250 and
HLA public epitopes of the class I MHC-antigens, based500 mg/L. We targeted to a 24-hour trough level range
on the amino acid residue system as proposed for UNOSafter three months between 50 and 150 mg/L. All patients
allocation [10]. Not only the degree of mismatching, butreceived 20 mg of prednisone starting on day 1; this
also the effect of sharing between donor and recipientdose was reduced by 2.5 mg every fortnight until a daily
of HLA antigens was studied. The term “mismatch” wasmaintenance dose of 10 mg was reached. Rejection epi-
used for the number of HLA antigens that donor andsodes were treated with 1 g of methylprednisolone intra-
recipient did not have in common, whereas the termvenously for 3 days or rabbit antithymocyte globulin for
“shares” was used for the number of corresponding HLA10 days, as previously described [8].
antigens between donor and recipient.
Definitions In our study population, the mean endogenous creati-
nine clearance at one year was approximately 50 mL/minTo exclude patients who were dialyzed for reasons
(Fig. 1). Arithmetical graft half-life was 70 years for graftsother than impaired graft function, we diagnosed DGF
with a creatinine clearance of more than 50 mL/min andretrospectively if the serum creatinine level increased,
18.5 years for grafts with a one-year creatinine clearanceremained unchanged, or decreased by less than 10% per
of less than 50 mL/min. Therefore, patients having aday immediately after surgery during three consecutive
creatinine clearance of more or less than 50 mL/mindays for more than one week. If a graft biopsy taken
were categorized as optimal or suboptimal function, re-within the first post-transplant week showed rejection,
spectively. We furthermore analyzed the data using ait was assumed that the graft did not have DGF, and it
graft function of more or less than 30 mL/min as thewas categorized as primary function (PF). Primary non-
dependent variable. This cut-off point represents thefunction (PNF) was defined as the absence of a decrease
mean minus one standard deviation and is a more strin-in the serum creatinine level that ultimately resulted in
gent outcome parameter. Arithmetical graft half-life wasgraft nephrectomy. PF was defined as a decrease of the
53 years for grafts with a creatinine clearance of moreserum creatinine level of more than 10% per day over
than 30 mL/min and seven years for grafts with a one-three consecutive days within the first week after surgery.
year creatinine clearance of less than 30 mL/min. ToGraft loss was defined as resumption of dialysis treat-
predict outcome at one year, patients experiencing graftments. Early graft loss was defined as graft loss within
loss within this year were categorized as having subopti-the first year after transplantation. Graft survival was
mal function at one year. To study the additional impactcensored for patient death with functioning graft. Renal
of DGF on outcome after the first year, we analyzed itsfunction at one year was calculated using the Cockroft-
Gault formula [9]: effect in different strata of renal function after one year.
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Table 1. Characteristics at time of transplantation
Total PF DGF
Risk factor (N 5 734) N 5 551 (75.1%) N 5 183 (24.9%)
Recipient
Age years 46613 46612 47614
Gender % female 38 38 39
Peak panel reactive antibodies (PRAH) % 31632 29631 36635
Current panel reactive antibodies (PRAC) % 12623 11622 14626
MAP before transplantation mm Hg 109616 110617 106616
Donor
Age years 37614 36614 42614
Gender % female 41.7 44.9 40.5
Cause of death
Trauma/cardiovascular % 47.5/52.5 49.5/50.5 41.8/58.2
Transplantation related
Gender mismatch
No mismatch % 54 56 46
Donor male-recipient female % 21 20 24
Donor female-recipient male % 25 23 30
Transplant status
First transplant % 83 76 79
.1 transplant % 17 24 21
Cold ischemia time hours 2967 2867 3067
Warm ischemia time minutes 2869 2869 2869
Immunosuppression at transplantation
Aza/pred. % 8 9 6
Immunosuppression at 6 months
Aza/pred. % 28.1 29.6 23.5
HLA
Mismatch 1.961.1 1.961.1 1.961.2
Shares 3.761.0 3.661.0 3.661.1
CREG
Mismatch 1.261.1 1.261.1 1.161.0
Shares 4.561.2 4.561.2 4.561.1
Number of rejection episodes ,1 year
1 % 23 23 24
2 % 23 20 30
.2 % 11 10 13
Type of rejection ,1 year
Interstitial % 36 34 41
Vascular % 14 12 21
Clinical % 8 8 7
Graft loss within 1 year % 13 11 19
Clearance at 1 year mL/min 53620 55620 47621
Data are expressed as mean 6 SD unless otherwise stated.
Statistical analysis RESULTS
Seven hundred ninety patients were included in theThe logistic regression model was used to determine
the factors significantly related to DGF, early graft loss, study; 24 (3.0%) were not analyzed because of PNF and
32 (4.1%) because of missing data on DGF. Demo-acute rejection, and renal function at one year in an
univariate way. The significant predictors of each param- graphic data are shown in Table 1. DGF was diagnosed
if the serum creatinine level increased, remained un-eter of renal function were next fitted in a multivariate
model. Step forward selection techniques were used to changed, or decreased less than 10% per day immedi-
ately after surgery during three consecutive days fordetermine significant risk factors. The risk is expressed as
odds ratio (OR) 1 95% CI. The impact of a suboptimal more than one week. Twenty-eight (11.8%) of the pa-
tients experiencing renal dysfunction in the first week,Cockroft clearance at one year on late graft loss was
studied using the Cox regression model. By using this making dialysis treatment necessary, had a biopsy-
proven acute rejection episode and were classified as PF.model, we were able to correct for the time of follow-
up to graft loss. The risk is expressed as a relative risk
Risk factors for delayed graft function(RR) 1 95% CI. We used the Kaplan–Meier survival
analysis (log-rank test) to compare graft failure in the In an univariate analysis, donor age of more than 50
years, MAP of less than 100 mm Hg, cold ischemia timedifferent strata of Cockroft clearance at one year. The
SPSS software package (9.0) was used for all analyses. (CIT) of over 28 hours, transplantation of a kidney from
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Table 3. Risk factors for suboptimal function (creatinine clearance
,50 mL/min) at one year after transplantation, including graft
loss in the first yeara
Variable Odds ratio 95% CIb
Delayed graft function 1.68 1.14–2.48
Donor age
.50 years 2.39 1.61–3.57
CREG-sharing
1–3 shares versus 4–8 shares 1.65 1.09–2.49
Number of acute rejection episodes
.1 2.66 1.87–3.78
Donor gender
Female versus male 1.99 1.42–2.78
Peak panel reactive antibodies
.50% 1.67 1.15–2.47
a Multivariate analysis
b 95% confidence interval
Table 4. Risk factors for a one-year creatinine clearance
,30 mL/min including graft loss within one yearaFig. 1. Frequency-distribution curve of the Cockroft clearances at one
year in 604 transplant patients.
Variable Odds ratio 95% CIb
Delayed graft function 1.81 1.17–2.81
Donor age
.50 years 2.11 1.35–3.29Table 2. Risk factors for delayed graft functiona
Immuno-suppressive regimen at time
of transplantationVariable Odds ratio 95% CIb
Aza/Pred. vs. CsA/Pred. 2.53 1.32–4.83
Donor age CREG-sharing
.50 years 2.21 1.49–3.26 1–3 vs. 4–8 shares 2.53 1.30–3.35
Recipient MAP before transplantation Number of acute rejection episodes
,100 mm Hg 2.08 1.43–3.03 $1 4.00 2.41–5.65
Cold ischemia time
a Multivariate analysis.28 hours 1.78 1.19–2.63
b 95% confidence intervalGender mismatch
No mismatch 1
Donor male-recipient female 1.09 0.69–1.73
Donor female-recipient male 1.55 1.02–2.35
Peak panel reactive antibodies rejection episodes within the first year. All of these fac-
.50% 1.7 1.15–2.55
tors were entered in a multivariate analysis and, as shown
a Multivariate analysis
in Table 3, remained significant with the exception ofb 95% confidence interval
donor cause of death and the warm ischemia time.
As a creatinine clearance of 30 mL/min was a more
stringent outcome variable for graft function, we also
a female donor to a male recipient, and peak panel reac- analyzed 30 mL/min at one year as the dependent vari-
tive antibodies of over 50% were associated with DGF. able. In the univariate analysis, DGF remained a signifi-
All of these factors were subsequently entered in a multi- cant risk factor, as were donor age of more than 50
variate analysis and remained significant (Table 2). years, female donor gender, and sharing of three or less
CREGs. The use of an initial Aza-based immunosup-
Risk factors for suboptimal graft function after one year pressive regimen, the occurrence of acute rejection epi-
To analyze the impact of DGF and other factors on sodes, and vascular rejection, were all associated with
graft function after one year, we used the creatinine suboptimal outcome. Table 4 shows the results of the
clearance of more or less than 50 mL/min as the depen- multivariate analysis. The incidence of DGF (OR 5 1.81,
dent variable. The univariate analysis revealed DGF as 95% CI, 1.17 to 2.81), the use of kidneys from donors
a risk factor for a suboptimal graft function after one older than 50 years (OR 5 2.11, 95% CI, 1.35 to 3.29), the
year. Other risk factors for suboptimal function included initial use of an Aza-based immunosuppressive regimen
donor age of more than 50 years, female donor gender, (OR 5 2.53, 95% CI, 1.32 to 4.83), the sharing of three
donor cause of death (cardiovascular vs. trauma), total or less CREGs (OR 5 2.53, 95% CI, 1.30 to 3.35), and
warm ischemia time, peak panel reactive antibodies of the incidence of acute rejection episodes (OR 5 4.00,
more than 50%, current panel reactive antibodies, shar- 95% CI, 2.41 to 5.65) remained significantly and indepen-
dently related to a graft function of less than 30 mL/ing of less than three CREGs, and the number of acute
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Table 5. Risk factors for the occurrence of acute rejection episodes
within one yeara
Variable Odds ratio 95% CIb
Delayed graft function 1.61 1.11–2.33
Mismatch HLA DR
$1 2.36 1.68–3.31
Peak panel reactive antibodies
.50% 1.60 1.12–2.30
a Multivariate analysis
b 95% confidence interval
min after one year. We were not able to analyze the
recipient’s age, weight, and gender as risk factors because
these variables were used in the Cockroft–Gault method
to estimate graft function.
Occurrence of acute rejection episodes within one
Fig. 2. Graft survival according to the incidence of delayed graft func-
year after transplantation tion (DGF). Kaplan–Meier estimates for transplants experiencing pri-
mary function (PF; , N 5 550; half-life 21.7 years) and experiencingDelayed graft function was associated with an increas-
DGF ( , N 5 183; arithmetical half-life 12.8 years). Log-rank test,
ing likelihood of acute rejection episodes in an univariate P 5 0.0005.
analysis, as were female donor gender, HLA-DR mis-
match, peak panel reactive antibodies of more than 50%,
and retransplant status of the recipient. HLA-sharing Table 6. Risk factors for graft loss within one yeara
correlated inversely with the incidence of acute rejection
Variable Odds Ratio 95% CIbepisodes. Table 5 shows the independent risk factors
Donor relatedfor acute rejection in the first year in the multivariate
Gender of donor 1analysis. The incidence of acute rejection episodes was Female vs. male 1.70 1.07–2.68
independently associated with DGF (OR 5 1.61, 95% Transplantation related
Immunosuppressive regimenCI, 1.11 to 2.33), an increase of HLA-DR mismatch
Aza/Pred. vs. CsA/Pred. 2.07 1.05–4.09(OR 5 2.36, 95% CI, 1.68 to 3.31), and peak panel Type of rejection ,1 year
reactive antibodies of more than 50% (OR 5 1.60, 95% No 1
Interstitial 2.64 1.33–5.22CI, 1.12 to 2.30).
Vascular 9.32 4.77–18.2
Clinical (no biopsy) 3.61 1.45–8.99
Influence of DGF on graft loss
a Multivariate analysis
b 95% confidence intervalFigure 2 shows the univariate Kaplan–Meier graft sur-
vival estimates of patients with PF and patients with
DGF. There was a significantly decreased graft survival
in patients with DGF, with an arithmetical graft half-life especially vascular rejection (OR 5 9.32, 95% CI, 4.77
of 12.8 years, compared with 21.7 years for patients not to 18.2), female donor gender (OR 5 1.70, 95% CI, 1.07
experiencing DGF. The main effect of DGF on graft to 2.68), and an Aza-based immunosuppressive regimen
loss seemed to take place in the first year, whereas after (OR 5 2.07, 95% CI, 1.05 to 4.09) remained indepen-
the first year, especially after six years, there was no dently associated with graft loss within the first year
difference in outcome (data not shown). The short- and (Table 6).
long-term graft losses were analyzed separately. Graft loss after the first year was associated in a univar-
In a univariate analysis, DGF was correlated with graft iate analysis with recipient age of less than 50 years and
loss within the first year, as were female donor gender, donor age of more than 50 years, the occurrence of acute
an Aza-based immunosuppressive regimen, CIT of more rejection episodes in the first year, and a CIT of more
than 24 hours, and the number and type of rejection than 34 hours. Increased sharing of HLA antigens, shar-
episodes. Sharing of HLA class-1 antigens correlated ing of four to eight versus three or less CREGs, and
inversely with graft loss. However, when the data were higher creatinine clearance at one year correlated in-
entered in a multivariate analysis, neither DGF (OR 5 versely with graft loss. DGF was not an independent risk
1.52, 95% CI, 0.92 to 2.53) nor cold ischemic time (OR 5 factor for graft loss after the first year (OR 5 1.58,
1.17, 95% CI, 0.72 to 1.88) remained a risk factor for 95% CI, 0.98 to 2.54). Table 7 shows the results of the
multivariate analysis. The occurrence of acute rejectiongraft-loss within the first year. Acute rejection episodes,
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Table 7. Risk factors of graft loss after one yeara
Relative
Variable risk 95% CIb
Recipient age
,50 years 1.70 1.00–2.86
Cold ischemia time
.34 hours 1.91 1.20–3.05
Occurrence of acute rejection episodes 1.38 1.11–1.71
a Multivariate analysis
b 95% confidence interval
episodes (OR 5 1.38, 95% CI, 1.11 to 1.71), recipient
age of less than 50 years (OR 5 1.70, 95% CI, 1.00 to
2.86), and a CIT of more than 34 hours (OR 5 1.90,
95% CI, 1.20 to 3.05) were all independent risk factors
for late graft loss. As soon as the Cockroft clearance
after one year was fitted in the model as a continuous Fig. 3. Graft survival according to graft function one year after trans-
plantation. Kaplan-Meier estimates for transplants experiencing a one-parameter, CIT and recipient age were no risk factors
year creatinine clearance of .50 mL/min [( ; N 5 339) and arithmeti-
anymore. Therefore, graft function at one year was a cal half-life of 70 years]; 40 to 50 mL/min [( ; N 5 135) and arith-
metical half-life of 30 years]; 30 to 40 mL/min [(. . . . . ; N 5 79) andstrong predictor of late graft outcome (RR 0.96, 95%
arithmetical half-life of 25 years]; ,30 mL/min [( . . .; N 5 56) andCI, 0.95 to 0.97 per mL/min). When graft function after
arithmetical half-life 7 years]. Log-rank test: P 5 0.009, . 50 mL/min
one year was divided in four strata of clearance of .50 vs. 40 to 50 mL/min; P , 0.001, .50 mL/min vs. 30 to 40 mL/min; P ,
0.001, .50 mL/min vs. ,30 mL/min; P 5 0.67, 40 to 50 mL/min vs. 30mL/min, clearance of 40 to 50 mL/min, clearance of 30
to 40 mL/min; P , 0.001, 40 to 50 mL/min vs. ,30 mL/min; P 5 0.003,to 40 mL/min, and clearance of ,30 mL/min, DGF had
30 to 40 mL/min vs. ,30 mL/min.
no additional effect on graft survival in any stratum
(Fig. 3).
studies on outcome of kidney transplantation should be
DISCUSSION considered.
In this retrospective study, we examined the risk fac- One of the possible mechanisms of the decreased glo-
tors and prognostic significance of DGF in renal trans- merular filtration rate in DGF seems related to tubular
plantation. In contrast to most other studies examining damage resulting from ischemia/reperfusion injury. Tu-
these parameters, we used a more stringent definition bular epithelial cell degeneration, tubular cell exfolia-
of DGF and analyzed the effect of DGF on graft function tion, interstitial edema, and interstitial cellular infiltra-
and survival independently. When DGF was diagnosed, tion are usually observed in biopsies in DGF [12]. In the
if the serum creatinine level increased, remained un- early phase, tubular obstruction by exfoliated tubular
changed, or decreased less than 10% per day immedi- cells results in a low net filtration pressure [13]. Later,
ately after surgery during three consecutive days for decreased sodium reabsorption results in afferent vaso-
more than 1 week, 183 (23.2%) patients experienced constriction and diminished glomerular filtration pres-
DGF, and 551 (69.7%) had primary graft function. If sures through the tubuloglomerular feedback mecha-
DGF was defined as the need of dialysis in the first week, nism [14]. Another factor related to DGF is brain death
244 (33.9%) of the patients would have been classified [15], but all the patients studied received a cadaveric
as having DGF. This means that 26% of patients who transplant.
were dialyzed postoperatively required dialysis treat- In the present study, we found that DGF was signifi-
ment for other reasons than DGF and that 10% of the cantly associated with the use of kidneys from older
patients experiencing DGF did not need dialysis treat- donors, particularly donors of more than 50 years of age,
ment. with the use of female donor kidneys transplanted into
Studies on transplant outcomes have traditionally fo- male recipients, a CIT of more than 28 hours, historic
cused on patient and graft survival as end points, without panel reactive antibodies of more than 50%, and a recipi-
consideration of graft function. Although graft loss is the ent’s pretransplant MAP of less than 100 mm Hg. Other
worst type of graft dysfunction, grafts with an impaired authors have also reported an increased incidence of
function require the most intense follow-up and thera- DGF in grafts from older donors [1, 16–18]. In human
peutic management and are economically most costly adults, total metabolism and renal function in terms of
glomerular filtration rate and renal blood flow decrease[11]. For this reason, graft function as a parameter in
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with age. This is associated with a decrease in the number mL/min as the cut-off point, DGF remained a risk factor
for poor graft function at one year. Although DGF is aof glomeruli, a decrease in the mean glomerular volume
[19], and interstitial fibrosis [20, 21]. It is conceivable strong risk factor for acute rejection episodes (OR 5
1.63, 95% CI, 1.11 to 2.33), the effect of DGF on graftthat such kidneys are more susceptible to additional in-
sults such as brain death and the transplantation proce- function was independent from the number of rejection
episodes. Long-term follow-up studies of native kidneysdure.
The higher incidence of DGF in female donor to male that have experienced acute tubular necrosis (ATN) sug-
gested a decrease in renal function in most cases, al-recipient combinations could be explained by the ab-
sence of estrogens in the male environment. In vitro though it was not associated with chronic failure [38, 39].
However, experimental studies in rats have shown thatstudies have shown that the administration of estrogens
leads to dilation of aortic rings [22], as has been described ischemia added to ongoing injury results in more severe
tissue damage [40]. Some authors found an effect ofin vivo in human coronary arteries [23]. It is therefore
conceivable that, when transplanted into a male environ- DGF on graft survival only in combination with acute
rejection episodes [3, 4, 41]. In our model, DGF had noment, female kidneys experience more vasoconstriction
and thus are more prone to DGF. An interesting obser- influence on graft loss at one year or after the first year.
Renal function at one year is probably a more importantvation is the finding that a low pretransplant blood pres-
sure level in the recipient confers a significant risk to determinant for late graft loss, as suggested in the Collab-
orative Transplant Study [42]. To study the effect of DGFDGF (Table 2). A stable hemodynamic condition and
possibly some degree of extracellular volume expansion on late outcome further, we stratified renal function after
one year in four strata (Fig. 3), and demonstrated thatare associated with good perfusion of the graft immedi-
ately after recirculation [24, 25]. Moreover, invasive he- renal function at one year is a risk factor of late graft
loss. When the contribution of DGF on late graft lossmodynamic studies have shown that a high pulmonary
artery [26] or central venous pressures [27] before, dur- was analyzed in these strata, there was no additional
effect of DGF on outcome.ing, and after the transplantation surgery correlate in-
versely with the incidence of DGF. As ischemia-reperfu- In this retrospective study, we found that DGF, de-
fined as the absence of a decline in serum creatinine ofsion injury results in the loss of autoregulation [28], the
beneficial effect of hypervolemia may result in an in- 10% or more in three consecutive days for more than one
creased glomerular perfusion flow and pressure. It is week after transplantation, has an independent effect on
unknown whether the reduced incidence of DGF in pa- graft function at one year as well as on the incidence of
tients treated with peritoneal dialysis, as found by some acute rejection episodes, but it does not seem to influence
authors [29, 30], is also based on an increased total extra- early or late graft loss. Graft survival after one year is
cellular fluid volume. A CIT of longer than 28 hours was mainly determined by the creatinine clearance at one
also independently associated with an increased risk of year, which suggests that the influence of DGF on graft
DGF, as found by others [31–34]. This is probably also survival is through graft function at one year. We also
the result of increased vasoconstriction [35] and renal found that the incidence of DGF is related to pretrans-
damage as a result of ischemic injury. Peak panel-reac- plantation MAP, probably as a marker for the effective
tive antibodies constitute another independent risk fac- circulating volume. Furthermore, the use of kidneys from
tor for DGF, as was noted by others [5]. In studies in older donors or from female donors transplanted into
which DGF was defined as the need of dialysis within the male recipients increases the risk for DGF. It remains
first week after transplantation, DGF could theoretically to be seen whether changing these risk factors improves
have included acute rejection episodes. Although we the rate of DGF as well as long-term function.
corrected for acute rejection episodes, peak panel-reac-
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